Cartesian Therapeutics, Inc.
RNACNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $184.54M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $5.60$11.00
- Volume (live)
- -
- Avg. volume (3M)
- 146.44K
Cartesian Therapeutics (RNAC) Stock Price & Financial Analysis
Cartesian Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $6.11 - $6.52 |
|---|---|
| 52-Week High | $11.00 |
| 52-Week Low | $5.60 |
| Open | $6.38 |
| Volume (last close) | 85.72K |
| Average Volume (3M) | 146.44K |
| Revenue (TTM) | 1.48M |
|---|---|
| Net Income (TTM) | -153.94M |
| Free Cash Flow (TTM) | -78.16M |
| EPS (TTM) | −$5.67 |
| Profit Margin | -10422.48% |
| Operating Margin | -6679.69% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 184.54M |
|---|---|
| Shares Outstanding | 29.86M |
| Price to Sales (P/S) | 124.94 |
| Price to Book (P/B) | -1.47 |
| EV/EBITDA | -0.70 |
| 50-Day MA | $8.18 |
|---|---|
| 200-Day MA | $7.69 |
| 1-Year Change | −28.56% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Cartesian Therapeutics at a Glance
As of the Oct 23, 2026 close, Cartesian Therapeutics (RNAC) has a market capitalization of $184.54M. The stock trades at 124.9× sales. Over the trailing twelve months it lost $153.94M on revenue of $1.48M and burned $78.16M of free cash flow. Revenue grew 44.0% year over year.
As of its latest reported balance sheet, it holds $147.61M in cash and securities against $57.05M of debt, a net cash position of $90.56M.
Cartesian Therapeutics does not currently pay a dividend.
The share price is down 28.6% over the past year. At $6.18 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $5.60 to $11.00, below its 200-day moving average of $7.69.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $32.60, 427.5% above the Oct 23, 2026 close.
Frequently Asked Questions About Cartesian Therapeutics
What is the current stock price for RNAC?
As of the Oct 23, 2026 close, RNAC stock trades at $6.18. The 52-week range is $5.60–$11.00, with a day range of $6.11–$6.52.
What is the P/E ratio for RNAC?
The P/E ratio (Price-to-Earnings) for RNAC is shown in the Key Statistics section. This valuation metric helps compare Cartesian Therapeutics, Inc. to industry peers.
Does RNAC pay dividends?
Cartesian Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for RNAC?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for RNAC is Buy. The average 12-month price target is $32.60, a 427.5% upside from the Oct 23, 2026 close of $6.18.
What is the market cap of RNAC?
As of the Oct 23, 2026 close, Cartesian Therapeutics's market capitalization is $184.5M, classifying it as a micro-cap company. Cartesian Therapeutics operates in the Healthcare sector within the Biotechnology industry.